Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

ADO-09 shown to be superior to insulin aspart in type 1 diabetes patients

June 3, 2021

Diverse cohort expands diabetes genomics

June 2, 2021

SCOHIA advances somatostatin SST5 receptor antagonist SCO-240 into phase I study

May 31, 2021

Enrollment opens in phase IIb study of ARO-APOC3 in severe hypertriglyceridemia

May 31, 2021

Studies reveal efficacy of OTL-101 gene therapy in treating ADA-SCID

May 27, 2021

Promising liver-specific AAV gene therapy for glycogen storage disease type 1A

May 27, 2021

Spruce Biosciences reports phase IIa data on tildacerfont in classic congenital adrenal hyperplasia

May 26, 2021

Sparrow Pharmaceuticals presents new data on SPI-62 for Cushing's syndrome

May 26, 2021

Phase I data presented for MEDI-6570 in patients with T2DM

May 26, 2021

GR antagonist CORT-125329 shows selectivity and activity in vitro and in vivo

May 26, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....